Insulin Biosimilar - Research Grade

Human

INSR

>1mg/ml

CHO Cells

Ersodetug Biosimilar - Research Grade (ICH5532)

https://www.imgt.org/mAb-DB/

ICH3002

P06213

3643

Blue ice

ICH5607 is an unconjugated, non-therapeutic recombinant analog of insulin, supplied strictly for research use only. It is built to reproduce the receptor-engaging biology of the originator insulin molecule, acting as an agonist ligand for the insulin receptor (INSR) rather than as an antibody. Because it is a research-grade reagent and not the clinical product, it is not intended for human or veterinary administration. The material is offered at low endotoxin levels (research grade <1 EU/mg, with ultra-low <0.5 EU/mg options) and in bulk mg-to-gram scale, making it suitable as a consistent, well-characterized standard across in-vitro and preclinical workflows. Typical research applications include use as a positive control in receptor-binding and signaling assays, benchmarking of INSR agonism, glucose-uptake and metabolic studies in cultured cells, comparability testing against other insulin analogs, and as a reference ligand when developing or validating INSR-directed reagents and detection systems. The low-endotoxin, lot-consistent, bulk format supports reproducible experimental designs where a defined insulin standard is required. The insulin receptor (INSR, UniProt P06213) is a disulfide-linked (alpha-beta)2 transmembrane receptor tyrosine kinase. The extracellular alpha subunits bind insulin, triggering a conformational change that activates the intracellular tyrosine kinase domains of the beta subunits. Autophosphorylation recruits and phosphorylates IRS adaptor proteins, driving the PI3K-AKT axis that governs glucose uptake (GLUT4 translocation), glycogen and lipid synthesis, and the RAS-MAPK axis that contributes to growth and mitogenic signaling. INSR exists in two splice isoforms (IR-A and IR-B) with differing ligand affinities and tissue distribution, and can form hybrid receptors with the closely related IGF-1 receptor. As the central mediator of insulin action, INSR is fundamental to metabolic homeostasis, and its dysregulation underlies insulin resistance and type 2 diabetes.

IR, Insulin receptor

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Insulin (anti-INSR) Biosimilar

Q: Is the Insulin biosimilar available in bulk mg to gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities for high-throughput and bulk in vivo experiments.

Q: Is this research-grade Insulin biosimilar suitable for in vivo use?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Insulin biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Insulin that binds INSR; for research use only.